Compare Adaptive Biotechnologies Corp (ADPT) vs Deere & Company (DE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Deere & Company — how do they compare? Adaptive Biotechnologies Corp trades at $19.96 (market cap $3.33B), while Deere & Company trades at $592.63 (market cap $162.94B). The key difference: Deere & Company is far larger — about 48.9× Adaptive Biotechnologies Corp's market cap, and Deere & Company pays a 1.07% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DE | |
|---|---|---|
Market Cap | $3.33B | $162.94B |
Sector | Health | Industrials |
52-Week High | $22.37 | $662.49 |
52-Week Low | $10.24 | $439.11 |
Enterprise Value | $3.19B | $217.76B |
Dividend Yield | — | 1.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Deere & Company (DE) trades at $603.61, down 2.84% on the day, with the stock showing strong technical momentum despite recent volatility. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $6.55 exceeding estimates by 15%. Fundamentals remain solid with 10.33% net margins and 18.51% ROE, though revenue declined to $44.67B in 2025. Analyst consensus points to 39% buy ratings with a $666.08 price target, representing 10% upside potential.
DE presents a mixed outlook with strong operational execution offset by cyclical headwinds in agricultural equipment demand. The precision agriculture platform offers growth potential, but investors face risks from economic sensitivity and margin pressure. Current valuation at 36x P/E appears elevated relative to historical norms, requiring continued earnings growth to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Deere & Company
Deere is the world's leading manufacturer of agricultural equipment, producing some of the most recognizable machines in the heavy machinery industry. The company is divided into four reportable segments: production and precision agriculture, small agriculture and turf, construction and forestry, and John Deere Capital. Its products are available through an extensive dealer network, which includes over 1,900 dealer locations in North America and approximately 3,700 locations globally. John Deere Capital provides retail financing for machinery to its customers, in addition to wholesale financing for dealers, which increases the likelihood of Deere product sales.
Read more on DE →
